HOOK (HOOKIPA Pharma) Other Current Payables: $0.00 Mil (As of Jun. 2025)


HOOK HOOKIPA Pharma Inc HOOK
50 GF Score
Price $1.15
GF Value $2.77
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HOOKIPA Pharma Other Current Payables?

HOOKIPA Pharma HOOK 50 Other Current Payables is $0.00 Mil as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100 and a GF Value™ of $2.77 (Possible Value Trap). The stock has 7 warning signs investors should review.

HOOKIPA Pharma's Other Current Payables for the quarter that ended in Jun. 2025 was $0.00 Mil.

HOOKIPA Pharma's annual Other Current Payables increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil) but then declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

HOOKIPA Pharma Other Current Payables Related Terms

HOOKIPA Pharma Other Current Payables Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma Other Current Payables Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Payables
Get a 7-Day Free Trial 0.00 0.00 -0.00 0.00 0.00

HOOKIPA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HOOK
50GF Score
HOOKIPA Pharma Inc HOOK
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
HOOKIPA Pharma (HOOK) has a Other Current Payables of $0.00 Mil as of Jun. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on HOOKIPA Pharma and its competitors.
Is HOOKIPA Pharma's Other Current Payables too high?
HOOKIPA Pharma's current Other Current Payables is $0.00 Mil. Overall, HOOKIPA Pharma has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Other Current Payables compare to COCP and LNAI?
HOOKIPA Pharma's Other Current Payables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.77, compared to a current price of $1.15 — trading 58.5% below its estimated fair value. The current Other Current Payables is $0.00 Mil. HOOKIPA Pharma's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Other Current Payables is $0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HOOKIPA Pharma (HOOK) Overvalued in 2026?

Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued. The current stock price of $1.15 is trading 58.5% below its estimated GF Value™ of $2.77. GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.

Key valuation signals for HOOK:

  • Other Current Payables: $0.00 Mil
  • GF Value™: $2.77 vs. price of $1.15 (58.5% below fair value)
  • GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score

Get the complete analysis for HOOK

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price
$2.77
GF Value